171 related articles for article (PubMed ID: 29596115)
1. Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
Turner KA; Manouchehri JM; Kalafatis M
Melanoma Res; 2018 Aug; 28(4):277-285. PubMed ID: 29596115
[TBL] [Abstract][Full Text] [Related]
2. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway.
Yi L; Zongyuan Y; Cheng G; Lingyun Z; Guilian Y; Wei G
Cancer Sci; 2014 May; 105(5):520-7. PubMed ID: 24612139
[TBL] [Abstract][Full Text] [Related]
3. TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment.
Manouchehri JM; Turner KA; Kalafatis M
Breast Cancer (Auckl); 2018; 12():1178223417749855. PubMed ID: 29434473
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
6. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
[TBL] [Abstract][Full Text] [Related]
7. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
8. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC; Reis CR; Schuringa JJ; Vellenga E; Quax WJ
J Biol Chem; 2014 Jan; 289(2):1071-8. PubMed ID: 24280212
[TBL] [Abstract][Full Text] [Related]
9. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
10. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
11. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells.
Ivanov VN; Zhou H; Hei TK
Cancer Res; 2007 Jun; 67(11):5397-407. PubMed ID: 17545621
[TBL] [Abstract][Full Text] [Related]
13. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants.
Hougardy BM; Reesink-Peters N; van den Heuvel FA; ten Hoor KA; Hollema H; de Vries EG; de Jong S; van der Zee AG
Int J Cancer; 2008 Sep; 123(6):1457-65. PubMed ID: 18567003
[TBL] [Abstract][Full Text] [Related]
14. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
17. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Van Schaeybroeck S; Kelly DM; Kyula J; Stokesberry S; Fennell DA; Johnston PG; Longley DB
Cancer Res; 2008 Oct; 68(20):8312-21. PubMed ID: 18922903
[TBL] [Abstract][Full Text] [Related]
18. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
Manouchehri JM; Kalafatis M
Anticancer Res; 2017 Dec; 37(12):6593-6599. PubMed ID: 29187434
[TBL] [Abstract][Full Text] [Related]
20. The Case Back on the TRAIL: Death Receptors as Markers for rhTRAIL Sensitivity.
Turner KA; Kalafatis M
J Appl Lab Med; 2017 Sep; 2(2):176-185. PubMed ID: 32630980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
